FDA Cybersecurity Deficiency Response for Surgical Robotics
Close FDA cybersecurity deficiencies for surgical robotic systems - multi-element SBOMs, control-loop threat models, and OR-network security architecture views.
Last reviewed March 2026 · Reviewed against the FDA Feb 3, 2026 final premarket cybersecurity guidance.
Deficiency letters for surgical robotic systems are usually heavy on three items: the multi-element SBOM that wasn't, the threat model that didn't include the OR-network and instrument-tower trust boundaries, and the security architecture view that conflated the patient cart with the surgeon console. Our 24-hour gap analysis identifies the architectural disclosures the reviewer is actually asking for - usually four discrete views: global system, multi-patient harm, updateability, and security use cases - and which are missing or insufficient in your current package.
The second cluster of deficiencies in this segment is essential-performance-adjacent: cyber findings on motion control or energy delivery treated as IT findings rather than as risk controls under IEC 60601-1's essential performance framework. Reviewers will reject responses that don't connect the cyber finding to the essential performance impact and the risk-control treatment. We rebuild that connection in your hazard analysis and risk file. The third cluster is around the postmarket plan: surgical robots are deployed in OR fleets and need a credible field-update story with a CVD program. We deliver the resubmission package as eSTAR-ready, structured for the reviewer who issued the letter, with traceability between deficiency item and response artifact.
FDA Deficiency Response engagement, end to end
Four phases, fixed fee, scoped to surgical robotics architecture from kickoff onward.
-
01
Scope + kickoff
Architecture review, attack-surface walkthrough, and threat-model alignment with your team. Written scope in 24 hours.
-
02
Threat-model alignment
Every STRIDE entry in your threat model is matched to a planned test case so reviewers see one-to-one coverage.
-
03
Test execution
Device, cloud, mobile, BLE/RF, and OTA channels exercised in parallel by senior engineers - not a single web-app scan.
-
04
Reviewer-ready report + retest
eSTAR-format report with findings, CVSS, remediation, and unlimited retests until every finding is closed.
What we see in Surgical Robotics fda deficiency response
The patterns we hit in this segment, this service, again and again.
-
Multi-element SBOM missing or single-document
Reviewer expects per-compute-element SBOM. Submission had one CycloneDX for the main node only.
-
Cyber findings disconnected from essential performance
Pen test results attached but not analyzed against essential performance. Resolved with risk-file linkage.
-
Field-update path not in security architecture view
'Updateability view' submitted but doesn't cover joint-controller or FPGA update channels. Rebuilt to actual architecture.
-
OR-network trust boundary absent from threat model
Threat model stops at the integration tower. Reviewer asks about imaging / energy-generator pass-through; gap addressed.
"Blue Goat Cyber takes the burden off our engineers and makes FDA cybersecurity requirements easy to understand. Their expertise and smooth process mean we can focus on our product, not the paperwork. The organized documentation, perfectly formatted for eSTAR, saves us countless hours."
Standard FDA Deficiency Response deliverables
The same deliverables the parent FDA Deficiency Response service ships with - tuned to your surgical robotics architecture.
- 24-hour gap analysis: We map every item in the deficiency letter against the specific FDA guidance section it references - so the response addresses what reviewers actually want, not what the letter superficially says.
- Remediation package: Every artifact identified in the gap analysis is rebuilt or updated - SPDF sections, SBOM, test evidence, or threat model - formatted for the eSTAR template and traceable to the deficiency items.
- Reviewer-ready response: The final package is structured for the FDA reviewer who issued the letter - changes are flagged, justified, and cross-referenced so they can close the deficiency without a second round.
- Post-submission support: We stay on the engagement until the deficiency is resolved - if FDA responds with a second round, we address it at no additional cost.
What lands in your eSTAR submission
Reviewer-format documents ready to drop straight into the cybersecurity attachments of your submission - no reformatting on your side.
- 24-hour gap analysis: We map every item in the deficiency letter against the specific FDA guidance section it references - so the response addresses what reviewers actually want, not what the letter superficially says.
- Remediation package: Every artifact identified in the gap analysis is rebuilt or updated - SPDF sections, SBOM, test evidence, or threat model - formatted for the eSTAR template and traceable to the deficiency items.
- Reviewer-ready response: The final package is structured for the FDA reviewer who issued the letter - changes are flagged, justified, and cross-referenced so they can close the deficiency without a second round.
- Post-submission support: We stay on the engagement until the deficiency is resolved - if FDA responds with a second round, we address it at no additional cost.
Standards that apply
The Surgical Robotics baseline, plus the call-outs that matter for fda deficiency response in this segment.
Segment-specific call-outs
IEC 60601-1 + 60601-2-77 essential-performance framing
Cyber findings on motion or energy delivery must be analyzed under essential performance - reviewers reject responses that don't.
AAMI TIR97 postmarket framework
Surgical-robotics fleets need a real postmarket cyber plan. Reviewers in this segment ask about it explicitly.
What's not in scope
We scope tightly on purpose. These items are either out-of-scope by design or belong in a separate engagement - we'll tell you up front, not after kickoff.
- Hospital enterprise IT network penetration testing
- Clinical efficacy or human-factors validation
- Physical security of manufacturing sites
- Source-code review (unless explicitly added as a separate engagement)
FDA Deficiency Response for Surgical Robotics - FAQs
The questions buyers in this segment actually ask before scoping a fda deficiency response engagement.
Go deeper on Surgical Robotics and premarket
A practical, ungated buyer's guide for medical device manufacturers evaluating cybersecurity partners, what goes wrong, why it costs you, and what to demand from your next engagement. Aligned to the FDA February 2026 premarket guidance.
A practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
The most common cybersecurity deficiencies in 510(k), De Novo, and PMA submissions, what triggers each one and how to fix it before you file. Aligned to the FDA February 2026 final guidance and Section 524B.
What happens if you fail an FDA cybersecurity inspection: the 483-to-consent-decree enforcement ladder and the commercial fallout for device makers.
SPDF vs SSDLC for medical devices. Why the FDA's Secure Product Development Framework demands more than a standard Secure SDLC, and what to add.
What medical device cybersecurity actually costs in 2026 - the four cost drivers, fixed-fee vs hourly pricing, premarket vs postmarket budget lines, and the cost of delay.
Other engagements for Surgical Robotics
Teams in this segment commonly bundle these alongside fda deficiency response.
Keep going
Scope a FDA Deficiency Response engagement for your surgical robotics program.
A 30-minute call with a senior engineer who has done this in surgical robotics before - not a sales rep.